Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet (KD) Combined With Immunotherapy in Adults With Advanced Melanoma, cSCC, or RCC.
NCT06896552 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2025-03-26
Summary
This clinical trial aims to evaluate whether a ketogenic diet (KD), when combined with immunotherapy, can improve immune function and treatment outcomes in patients with advanced melanoma, cutaneous squamous cell carcinoma (cSCC), or renal cell carcinoma (RCC).
Why Is This Study Important? Immunotherapy is a promising cancer treatment, but not all patients respond well. Research suggests that diet, particularly a high-fat, low-carbohydrate ketogenic diet, may help boost the immune system and make treatments more effective.
What Will This Study Examine?
Researchers want to understand:
Is the ketogenic diet well-tolerated for cancer patients? Does the diet improve immune responses and treatment effectiveness?
How Will the Study Work?
Participants will be placed into one of two groups:
Ketogenic Diet (KD) Group: A structured high-fat, low-carb diet (intermittent schedule: 2 weeks on, 1 week off).
Standard Diet (SD) Group: A typical diet with no major changes. Throughout the study, a dietitian will closely support and guide you. Both groups will continue their standard immunotherapy treatment.
What Will Participants Do? Write their food intake three times a week to help assess dietary adherence Follow their assigned diet for 10 weeks Have weekly check-ins with a dietitian (in-person at the hospital or via phone) Have weekly blood glucose and ketone level checks using a home device. Provide monthly blood samples to measure immune response during routine immunotherapy infusions Provide stool samples for gut microbiome analysis at the start and end of the study Measure Monthly Weight, body composition, and resting calorie burn Complete quality-of-life questionnaires
What Are the Potential Benefits? Improved response to immunotherapy Better understanding of how diet influences cancer treatment Potential for a new supportive strategy for cancer care
This study may help uncover ways to enhance cancer treatment through personalized nutrition.
Conditions
- Cancer
- Immunotherapy
- Ketogenic Diet
Interventions
- DIETARY_SUPPLEMENT
-
Ketogenic diet
Ketogenic Diet as an Adjunct to Immunotherapy: Unlike many trials focused on chemotherapy or targeted therapies, this study specifically investigates the synergistic effects of the ketogenic diet with immune checkpoint inhibitors (ICIs), a promising approach for enhancing immunotherapy efficacy. The diet's high-fat, low-carbohydrate regimen is designed to shift metabolism towards ketone bodies and fatty acid utilization, potentially modulating immune responses and tumor immunogenicity in a way that standard diets do not.
Sponsors & Collaborators
-
Rabin Medical Center
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-30
- Primary Completion
- 2027-04-30
- Completion
- 2027-04-30
Countries
- Israel
Study Locations
More Related Trials
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
NCT06239220 ·Status: RECRUITING ·Phase: PHASE2
-
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
NCT05588453 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
NCT01369888 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT04119024 ·Status: RECRUITING ·Phase: PHASE1
-
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
NCT00003102 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
NCT03387111 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
NCT00003022 ·Status: COMPLETED ·Phase: PHASE1
-
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers
NCT03388632 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
NCT01350401 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
NCT00399113 ·Status: COMPLETED ·Phase: PHASE1
-
Multiepitope Peptide Vaccination in Melanoma
NCT00153569 ·Status: UNKNOWN ·Phase: PHASE2
-
Neo-adjuvant Immunotherapy Master Trial for Localized Cancers
NCT07262489 ·Status: RECRUITING ·Phase: PHASE2
-
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
NCT00203866 ·Status: TERMINATED ·Phase: PHASE2
-
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
NCT04006522 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma
NCT00005617 ·Status: COMPLETED ·Phase: PHASE1
-
Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00091338 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
NCT02580747 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.
NCT00688090 ·Status: COMPLETED ·Phase: PHASE1
-
Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
NCT07128680 ·Status: RECRUITING ·Phase: PHASE1
-
Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer
NCT00093522 ·Status: UNKNOWN ·Phase: PHASE2
-
Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors
NCT00855452 ·Status: COMPLETED ·Phase: PHASE2
-
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
NCT02678741 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer
NCT00631072 ·Status: COMPLETED ·Phase: PHASE1
-
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
NCT02650986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy
NCT00503568 ·Status: COMPLETED ·Phase: PHASE1